The National Cancer Institute (NCI) has awarded a $535,334 Project Grant (CFDA 93.396 Cancer Biology Research) to Albert Einstein College of Medicine to conduct research on the role of androgen signaling in prostate cancer tumorigenesis. The project will examine the non-autonomous effects of androgen receptor (AR) activation in prostatic stromal cells on promoting oncogenesis and tumor development in prostate epithelial cells. Specifically, the research aims to investigate how stromal AR signaling in GLI1-expressing cells regulates insulin-like growth factor and Wnt/β-catenin pathways to influence prostate epithelial transformation. The award period is from January 1, 2025 through December 31, 2029. This research seeks to provide new insights into the stromal contribution to prostate cancer initiation and progression that could inform the development of improved therapeutic strategies for advanced prostate cancer.
Generated 2/25/25, 4:03 AM